Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,440 GBX | -0.26% |
|
+0.18% | +17.45% |
01:11pm | G1 Therapeutics' breast cancer drug fails in late-stage trial | RE |
09:55am | ASTRAZENECA : Barclays maintains a Buy rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.45% | 244B | |
+51.63% | 796B | |
+40.94% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+3.89% | 228B | |
+12.82% | 214B | |
+6.99% | 165B | |
-3.65% | 157B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Rare Inflammatory Disease Drug for Adults Wins First-in-Class Nod in China